HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC)
Clinical trials for HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC) explained in plain language.
Never miss a new study
Get alerted when new HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC) trials appear
Sign up with your email to follow new studies for HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a common breast cancer drug keep ovarian cancer at bay?
Disease control Recruiting nowThis study tests whether adding letrozole, a hormone therapy used in breast cancer, to standard maintenance treatment can delay the return of ovarian cancer. About 540 women with estrogen-receptor-positive ovarian cancer who have completed initial surgery and chemotherapy will re…
Matched conditions: HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC)
Phase: PHASE3 • Sponsor: Swiss GO Trial Group • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New drug trial targets hard-to-treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BMS-986463 in people with advanced ovarian, uterine, or lung cancer that has spread or cannot be removed by surgery. The main goals are to check the drug's safety and find the best dose. About 240 participants will receive increasing…
Matched conditions: HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC)
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Can a tumor 'Fingerprint' improve ovarian cancer care? new study aims to find out
Knowledge-focused Recruiting nowThis study is testing whether giving doctors extra, detailed information about a patient's tumor helps them choose a better treatment plan for advanced ovarian cancer. About 60 newly diagnosed patients will be split into two groups: one gets standard care, and the other gets a pe…
Matched conditions: HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC)
Phase: NA • Sponsor: Swiss GO Trial Group • Aim: Knowledge-focused
Last updated May 14, 2026 12:02 UTC